** Vigil Neuroscience shares VIGL.O jump 245% to $8 premarket as Sanofi to acquire firm in $470 million deal to boost its neurological pipeline
** Sanofi would pay $8 per share to Vigil shareholders, who would also be eligible for a contingent value right $(CVR)$ of $2 per share
** CVR is tied to a drug that Vigil is developing for the potential treatment of Alzheimer's disease
** Shares of Vigil, which have lost a third of their value in the past 12 months, closed at a valuation of about $100 mln on Wednesday
(Reporting by Medha Singh)
((medha.singh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。